GIP mediates the metabolic effect of corticosterone (Bates et al
But if your goal is fat loss and improved body composition, the scale is a poor judge
JACC study: GLP-1 RA with SGLT2 inhibitors in HFpEF A retrospective cohort study analyzed 29,922 patients with T2D and obesity-related HFpEF on SGLT2 inhibitors, comparing 7,044 patients who received additional GLP-1 RA therapy (including semaglutide) with 7,044 on SGLT2 inhibitors alone over 12 months [30]
An exploratory cohort of subjects was also evaluated to assess changes to dose regimen
Another review of studies involving BPC-157, as well as TB-500, GHK-Cu, and several other peptides, similarly found a lack of evidence to support clinical use of the substances
With a significant market presence in the U.S